FDA CDER Letter to USPTO, Apr 22 (FDA-2020-E-2185-0006)
Summary
FDA's Center for Drug Evaluation and Research (CDER) issued a letter to the U.S. Patent and Trademark Office on April 22, filed as document FDA-2020-E-2185-0006 on regulations.gov. The document is listed as an attachment available for download but the full letter content is not displayed in the source page. This appears to be a patent-related submission from FDA's drug evaluation center to the USPTO.
About this source
GovPing monitors Regs.gov: Food and Drug Administration for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 379 changes logged to date.
What changed
FDA's Center for Drug Evaluation and Research (CDER) submitted a letter to the U.S. Patent and Trademark Office on April 22, filed as document FDA-2020-E-2185-0006 on regulations.gov. The source is a document index page on regulations.gov with no full-text content displayed; the letter itself is available only as an attachment download.
Affected parties monitoring FDA regulatory submissions related to patent matters should retrieve the attachment to review the substantive content of the CDER correspondence to USPTO. This document type typically relates to patent term extensions, listing decisions, or other drug patent matters within FDA's purview.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Content
There are no documents available to view or download
Attachments 1
Letter to U.S. Patent and Trademark Office
More Information
- Author(s) CDER
Download
Related changes
Get daily alerts for Regs.gov: Food and Drug Administration
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from FDA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when Regs.gov: Food and Drug Administration publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.